# UNION therapeutics A/S

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/uniontherapeutics).

## Overview

UNION therapeutics A/S is a Danish biopharmaceutical company focused on developing and commercializing small-molecule therapies for inflammatory and infectious skin diseases. Its main asset is orismilast, a PDE4B/D inhibitor being advanced for diseases such as atopic dermatitis and hidradenitis suppurativa, with global rights structured through selective out-licensing in Greater China.

## Products & services

• Orismilast drug development
• Topical orismilast formulation rights
• PDE4B/D inhibitor platform
• Licensing and regional partnering
• Clinical-stage dermatology therapeutics

- **Clinical-stage drug candidate** (80%) — Development of orismilast and related formulations for dermatology indications.
- **Licensing and regional rights** (20%) — Out-licensing and option agreements for regional commercialization rights.

- Orismilast drug development
- Topical orismilast formulation rights
- PDE4B/D inhibitor platform
- Licensing and regional partnering
- Clinical-stage dermatology therapeutics

## Customers

The company’s direct counterparties are pharmaceutical and biotech partners that license regional rights or collaborate on development programs. Its eventual end customers are patients and physicians treating inflammatory skin diseases such as atopic dermatitis and hidradenitis suppurativa. Commercial value depends on demonstrating clinical efficacy, tolerability, and regulatory suitability across target markets.

- **Regional licensing partners** (primary) — Licensees or option holders buying rights for specific territories and indications.
- **Clinical investigators and development collaborators** (secondary) — Research partners and trial sites advancing orismilast data packages.
- **Dermatology patients** (primary) — Patients with atopic dermatitis, hidradenitis suppurativa and related conditions.
- **Prescribing physicians** (secondary) — Specialist physicians choosing therapies based on efficacy and safety.

- Pharma partners licensing regional rights to orismilast
- Biotech collaborators supporting development programs
- Dermatologists and specialist prescribers
- Patients with chronic inflammatory skin disease
- Healthcare systems adopting approved therapies

## Geography

UNION therapeutics is headquartered in Denmark and operates as a global development company with worldwide rights to its lead asset except for China, Hong Kong, Taiwan and Macau, which are licensed to Innovent Biologics. The business is therefore shaped by a global patent and partnering footprint rather than manufacturing geography, with regional commercialization rights split between UNION and its partner.

- Headquartered in Denmark
- Global rights retained outside Greater China
- Innovent Biologics holds exclusive Greater China rights
- Revenue is tied to licensing and delivery location
- Geography matters through territory-specific IP and partnering

## Strategy

UNION therapeutics’ strategy centers on advancing orismilast through clinical development and expanding the evidence base needed for partnering and eventual commercialization. Regional licensing, especially the Greater China arrangement, is used to monetize non-core territories while retaining broader worldwide rights.

- **Clinical development of orismilast** (short-term) — Clinical proof is the main driver of asset value and partnering leverage.
- **Regional partnering and licensing** (medium-term) — Territory deals can monetize rights while preserving upside in other markets.
- **Broaden therapeutic and formulation options** (medium-term) — Multiple indications and topical options can enlarge the addressable market.

- Advance orismilast through clinical development
- Build clinical data for dermatology indications
- Use regional licensing to fund development
- Retain worldwide rights outside partnered territories
- Strengthen the asset through formulation and indication expansion

## Risks

The company is exposed to clinical, regulatory, and partnering risk because value depends on successful development of a single lead asset. It also faces typical biotech financing and dilution risk, plus counterparty and territory concentration risk where a regional partner controls commercialization in Greater China.

- **Clinical development failure** [critical] — Orismilast is still a development-stage asset, so poor efficacy or safety data would impair value.
- **Regulatory approval risk** [high] — Even positive data may not translate into approval across target markets.
- **Partner concentration and territorial dependence** [medium] — Commercial rights in Greater China are controlled by a single partner, reducing direct control.
- **Financing and dilution risk** [high] — Clinical-stage biotech businesses typically rely on external capital before product revenue scales.

- Clinical trial failure could reduce asset value
- Regulatory approvals may not be granted
- Dependence on a single lead molecule creates concentration risk
- Partner concentration in Greater China can limit control
- Biotech funding needs can drive dilution or refinancing risk

## Accounting

The most important accounting judgments relate to revenue recognition on licensing arrangements, especially determining whether milestones and license fees are recognized at a point in time or over time. The company also uses level 3 fair value estimates for warrants, put options and convertible loans, and its intangible assets not yet available for use are tested for impairment annually or when indicators arise.

- **License revenue recognition** — Can shift timing of reported revenue between periods
- **Milestone and variable consideration** — Affects recognition of partnering income
- **Level 3 fair value measurements** — Can create significant non-cash gains or losses
- **Impairment of intangible assets** — Can materially affect asset carrying values and profit

- License revenue depends on point-in-time vs over-time assessment
- Milestone revenue recognition depends on probability constraints
- Level 3 valuations affect warrants, put options and convertible loans
- Intangibles not yet available for use require impairment testing
- Warrant accounting affects equity and liability presentation

---

*Last updated: 2026-10-24T15:20:45.574762+00:00*